Small molecule inhibitors have been successfully developed to target the DEAD‐box RNA helicases eukaryotic initiation factor‐4A, DEAD‐box RNA helicase 3 (DDX3), and DDX41 [11, 12, 13, 14], with the DDX3 inhibitor RK‐33 now in clinical trials for lung cancer patients. Here, DDX3X is linked to lung carcinoma.